Testing Lifespan/Healthspan-Extension Interventions in the Models of Alzheimers Disease (AD/ADRD) (R43/R44 Clinical Trial Not Allowed)

Archived

National Institutes of Health

View on Grants.gov 📝 Build a proposal template ★ Save

Description

This funding opportunity (FOA) encourages small business-based (SBIR) research and development of commercial pharmaceutical interventions to extend lifespan and/or healthspan, to prevent, treat, and/or slow the progression of symptoms associated with Alzheimer's disease (AD) and Alzheimer's disease related dementia (ADRD) in human cells and/or tissue, in-vitro models, and/or non-human animals.

Who can apply

  • Small businesses

Contact

NIH OER Webmaster<br/>FBOWebmaster@OD.NIH.GOV<br/>
FBOWebmaster@OD.NIH.GOV

Key dates & funding
  • PostedDec 20, 2017
  • ClosesJan 5, 2021
  • Award ceiling$350,000
  • Program funding$4,000,000
  • CFDA93.866
Categories
Health

Pro insight

Edit and export this grant’s proposal template, plus deadline reminders, similar-grant suggestions, and funder history — all available with Pro.

Unlock with Pro